

INTERIM GUIDANCE FOR COUNTRY VALIDATION OF VIRAL HEPATITIS ELIMINATION

JUNE 2021

TECHNICAL REPORT

INTERIM GUIDANCE FOR COUNTRY VALIDATION OF VIRAL HEPATITIS ELIMINATION

JUNE 2021

TECHNICAL REPORT

Interim guidance for country validation of viral hepatitis elimination

ISBN 978-92-4-002839-5 (electronic version)

ISBN 978-92-4-002840-1 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout: 400 Communications.

CONTENTS

Acknowledgements	v
Acronyms and abbreviations	viii
Glossary	ix
Executive summary	xi
 SECTION ONE: BACKGROUND	 1
1. Introduction and background	2
1.1. Epidemiology of viral hepatitis B and C infection	2
1.2. Global Health Sector Strategy on viral hepatitis 2016–2021	4
1.3. Key interventions for the prevention, diagnosis, treatment and care of viral hepatitis	5
1.4. Progress on the global response	8
1.5. Progress on regional strategies and country programmes	11
2. Elimination of viral hepatitis: principles and practice	14
2.1. Guiding principles in the validation of elimination of viral hepatitis	14
2.2. The national planning process	15
2.3. Approaches to the country validation of elimination of viral hepatitis B and C as a public health problem	16
 SECTION TWO: IMPACT AND PROGRAMME CRITERIA FOR ELIMINATION AND MEASUREMENT APPROACHES	 23
3. Validation of elimination of mother-to-child transmission of hepatitis B: targets, indicators and measurement	24
3.1. Background	24
3.2. Indicators and targets for validation of EMTCT of hepatitis B	25
3.3. Approaches to measuring indicators for validation of EMTCT of hepatitis B	33
4. Validation of reduction in HCV transmission and incidence: targets, indicators and measurement	36
4.1. Background	36
4.2. Indicators and targets for validation of the elimination of HCV transmission	36
4.3. Approaches to measuring indicators for validation of elimination of HCV transmission	39

5. Validation of mortality reduction from HBV and HCV: targets, indicators and assessment	43
5.1. Background	43
5.2. Indicators and targets for validation of reduction in HBV and HCV mortality for elimination	43
5.3. Approaches to measuring indicators for hepatitis B and C mortality	46
6. Implementation considerations for validation of elimination	52
6.1. Ensuring the quality of strategic information systems and data	52
6.2. Ensuring the quality of diagnostics, laboratory services and medicines	54
6.3. Ensuring the quality of prevention, diagnosis and treatment services, including that of the vaccination programme	54
6.4. Ensuring community engagement, human rights and equity in access to services	56
SECTION THREE: GOVERNANCE AND PROCESS FOR VALIDATION	59
7. Validation of elimination: the process of governance	60
7.1. Overview	60
7.2. Process of governance and integration within the existing infrastructure for validation of elimination	62
7.3. The submission process	63
7.4. Decisions on the maintenance of validation, revalidation and reversal of validation	64
7.5. National level	64
7.6. Regional level	66
7.7. Global level	67
References	68
ANNEXES	75
Annex 1. National elimination report template	75
Annex 2. Checklist for supporting evidence of implementation considerations for validation of elimination	76

ACKNOWLEDGEMENTS

Many professionals from a range of backgrounds and specialities have contributed to the development of this guidance. WHO is sincerely grateful for their time and support.

Validation of elimination guidance group

Meeting Co-chairs: Part 1 meeting (June 2020): Benjamin Cowie (The Peter Doherty Institute for Infection and Immunity, Australia) and Njie Ramatoulie (The Gambia Hepatitis Intervention Study, The Gambia) and Part 2 meeting (November 2020): Benjamin Cowie (The Peter Doherty Institute for Infection and Immunity, Australia) and Annette Sohn (TREAT Asia/amfAR, Thailand).

Laith Abu-Raddad (Weill Cornell Medicine, Qatar); Paige Armstrong (Global Health Office, Division of Viral Hepatitis, Centers for Disease Control and Prevention, United States of America, USA); Francisco Averhoff (Global Health Office, Viral Hepatitis, Centers for Disease Control and Prevention, USA); Alioune B. Coulibaly (World Hepatitis Alliance, Mali); Benjamin Cowie (The Peter Doherty Institute for Infection and Immunity, Australia); François Dabis (Agence Nationale de Recherches sur le Sida et les Hépatites Virales, France); Maegan Ashworth Dirac (Institute for Health Metrics and Evaluation, University of Washington, USA); Maria Donatelli (Coalition Plus, France); Dimitri Donchuk (Médecins Sans Frontières, Belgium); Gregory Dore (Kirby Institute University of New South Wales, Australia); Erika Duffell (European Centre for Disease Prevention and Control (ECDC), Sweden); Bryn Gay (Treatment Action Group, USA); Satish Gopal (Center for Global Health, National Cancer Institute, USA); Charles Gore (Medicines Patent Pool and The Hepatitis Fund, Switzerland); Mauro Guarinieri (International Network of People Who Use Drugs, Switzerland); Margaret Hellard (Burnet Institute, Australia); Zheng Hui (National Immunization Program, Chinese Center for Disease Control and Prevention, China); Naveed Zafar JanJua (British Columbia Centre for Disease Control, Canada); Youngmee Jee (Global Center for Infectious Diseases College of Medicine, Seoul National University, Korea); Alexandra King (Indigenous Health and Wellness University of Saskatchewan, Canada); Craig McClure (Clinton Health Access Initiative, USA); Susie McLean (The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland); Chris Munoz (Yellow Warriors Society Philippines, Philippines); Angela Mushavi (Global Validation Advisory Committee for Elimination of Mother-to Child Transmission of HIV and Syphilis, Zimbabwe); Shevanthi Nayagam (Imperial College London, United Kingdom of Great Britain and Northern Ireland, UK); Oudou Njoya (University of Yaoundé, Cameroon); Muazzam Nasrullah (Division of Viral Hepatitis Centers for Disease Control and Prevention, USA); Njie Ramatoulie (The Gambia Hepatitis Intervention Study, The Gambia); Homie Razavi (Center for Disease Analysis, USA); Annette Sohn (TREAT Asia, Thailand); Mark Sonderup (University of Cape Town, South Africa); Eyasu Teshale (Division of Viral Hepatitis, Centers for Disease Control and Prevention, USA); Karin Timmermans (UNITAID, Switzerland); Romane Theoleyre (UNITAID, Switzerland); Rania A. Tohme (Global Immunization Division, Centers for Disease Control and Prevention, USA); Peter Vickerman (University of Bristol, UK); Su Wang (World Hepatitis Alliance, USA); Annemarie Wasley (Global Immunization Division, Centers for Disease Control and Prevention, USA); John W. Ward (Task Force for Global Health, Coalition for Global Hepatitis Elimination, USA); Carolyn Wester (Global Health Office, Division of Viral Hepatitis, Centers for Disease Control and Prevention).

Country ministries of health

Ekaterine Adamia (MoDP & LHSA, Georgia); Wegene Adugna (Hepatitis Program Ministry of Health, Ethiopia); Marceline Dahl-Regis (Ministry of Health, The Bahamas); Budbazar Enkhtuya (Hepatitis, Surveillance Department, National Center for Communicable Diseases, Mongolia); Mohamad Hassany (National Hepatology and Tropical Medicine Research Institute, Ministry of Health, Egypt); Glaucio Junior (National Viral Hepatitis Program, Brazil); Maria Isela Lantero (National HIV/AIDS/STI Programme, Cuba); Maurice Mbella (Service de la Lutte contre les Infections Sexuellement Transmissibles et les Hépatites Virales, Cameroon); Huma Qureshi (National Focal Point Hepatitis, Pakistan); Cielo Yaneth Rios (HIV, STIs and Viral Hepatitis Team, Colombia); Janvier Serumondo (Hepatitis programme at Rwanda Biomedical Centre, Rwanda); Ye Shaodong (National Center for AIDS/STD Control and Prevention, China); Anita Suleiman (HIV/STI/Hepatitis C Sector, Malaysia); Maia Tsereteli (National Center for Disease Control and Public Health, Georgia); Montinee Vasantiuppapokakorn (Division of AIDS and STIs, Department of Disease Control, Ministry of Public Health, Thailand)

WHO regional and country offices

African Region: Hugues Lago (Brazzaville, Congo); Julien Kabore (Vaccine Preventable Diseases, Congo); Frank Lule (Brazzaville, Congo); Casimir Manzengo (Brazzaville, Congo); Richard Mihigo (Brazzaville, Congo); Etienne Kembou, (WHO Country Office, Cameroon); Jules Mugabo Semahore (WHO Country Office, Rwanda);

Region of the Americas: Massimo Ghidinelli (Washington, DC, USA); Alba Maria Roperio (Washington, DC, USA); Leandro Sereno (Washington, DC, USA); Alba Vilajeliu (Washington, DC, USA);

South-East Asia Region: Mukta Sharma (Delhi, India); B.B. Rewari (Delhi, India); Sigrun Roesel (Delhi, India); Fabio Mesquita (WHO Country Office, Yangon, Myanmar); Vimlesh Purohit (WHO Country Office, Delhi, India);

European Region: Nicole Seguy (Copenhagen, Denmark); Antons Mozalevskis (Copenhagen, Denmark); Giorgi Kuchukhidze (Copenhagen, Denmark); Liudmila Mosina (Copenhagen, Denmark); Marcelo Naveira (Copenhagen, Denmark); Nino Mamulashvili (WHO Country Office in Georgia, Tbilisi);

Eastern Mediterranean Region: Yvan Hutin (Cairo, Egypt); Quamrul Hasan (Cairo, Egypt); Bridget Akora Mugisa (Cairo, Egypt); Ahmed Alaama Sabry (Cairo, Egypt); Alaa Hashish (WHO Country Office, Egypt); Muhammad Safdar Pasha (WHO Country Office, Pakistan)

Western Pacific Region: Naoko Ishikawa (Manila, Philippines); Yoshihiro Takashima (Manila, Philippines); Po-Lin Chan (Manila, Philippines); Anne Brink (Manila, Philippines); Linh-Vi Le (Manila, Philippines); Robert Allison (Manila, Philippines); Zhongdan Chen (WHO Country Office, China)

International Agency for Research on Cancer (IARC/WHO), France: Catherine de Martel (Early Detection, Prevention and Infections Branch)

WHO headquarters, Geneva, Switzerland

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23836

